Automated Cell Analysis Systems Driving High-Content Screening/Imaging
November 06, 2018
WELLESLEY, Mass., Nov. 6, 2018 – The increasing adoption of high-content screening in research and development is contributing to growth of this market. The imaging of cell function is important to understanding the underlying functional biology associated with new therapeutic targets. A new BCC Research study projects that by 2023, the global market for high-content screening/imaging will be worth $1.7 billion.
High-content screening integrates the instrumentation, application software, reagents, sample preparation and informatics/bioinformatics required to rapidly flow from producing data and generating information to ultimately creating new cellular knowledge. The method allows relatively high-throughput screening of cells. From an estimated $915 million in 2018, a five-year compound annual growth rate of 13.1% is projected, according to a new report by BCC Research, High-Content Screening/Imaging: Technologies and Global Markets.
High-content screening is being implemented in oncology, neuroscience and oncology research, including primary and post-primary compound screening. Recently, high-content approaches have been used extensively in stem cell biology. There is demand for high-content imaging within fully automated screening laboratories.
Research Highlights
- High-content screening can analyze a large amount of data in very little time. This technique has been developed to collect quantitative data from cell populations.
- Software and analytics is the fastest-growing market segment. High-content screening software stores image data and analyzes systems that support a wide range of file formats, allowing visualization of images regardless of origin.
- With the help of 3D high-content screening, 3D cell cultures are increasingly being implemented in early drug discovery.
“The rapid adoption of high-content screening in the pharmaceutical industry and academic research centers shows the importance of this information-rich screening tool,” said BCC Research analyst Anuj Pathak. “High-content screening imaging systems have incorporated improvements to meet users’ demands of greater flexibility and the growing requirements of assays that involve complex cellular disease models.”
Equipment Expense Is a Market Restraint
The high cost of high-content screening instrumentation is the primary factor restraining market growth. The price of machinery and instrumentation prohibits a small-economy country or research organization from purchasing high-content screening equipment. Inadequate infrastructure and less funding for research and development in emerging countries will also hinder the market because installation and maintenance costs are also very high.
Editors/reporters requesting analyst interviews should contact Eric Surber at press@bccresearch.com.
High Content Screening/Imaging: Technologies and Global Markets( BIO166A )
Publish Date: Oct 2018
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.
BCC Library Membership Benefits
Unlimited Access to Market Research Reports for Academic Institutions and Corporations.
Custom Research
Tailored solutions across industries for your unique business needs.
More in Cell Biology
- Biotech Equipment Market Projected to Reach $143.9 Billion Globally by 2030
- Global Protein Drugs Market to Reach $655.7 Billion by 2029
- Chromatography Technologies Powering the Future of Biopharmaceuticals
- Assisted Reproductive Technologies Market Set for Expansion
- Genome Editing Market to Grow at 16.9% CAGR Through 2030
Reports from Cell Biology
Recent News
- Targeted Alpha Therapies Market to Grow at 44% CAGR Globally by 2030
- Global Anti-Parkinson's Drugs Markets Projected to Reach $9.2 Billion by the End of 2030
- BCC Research Forecasts 7.5% CAGR for Pen Needles Market Through 2030
- Rheumatoid Arthritis Therapies Market to Hit $41.1B by 2030
- Healthcare PPE Industry to Surpass $13 Billion by 2030 Amid Rising Safety Standards
